FDA Seeks Renewal of Food Traceability Records
Published Date: 6/11/2026
Notice
Summary
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
Analyzed Economic Effects
7 provisions identified: 3 benefits, 4 costs, 0 mixed.
Mandatory Food Traceability Recordkeeping
If you are a food business that manufactures, processes, packs, holds, receives, distributes, transports, or imports food in the United States, you must establish and maintain records identifying the immediate previous sources and immediate subsequent recipients of food under 21 CFR part 1, subpart J and subpart S (OMB control number 0910-0560).
Extra Records for High‑Risk Foods (FTL)
If your business handles foods FDA has listed on the Food Traceability List (FTL), you must keep additional records linking traceability lot codes and data for critical tracking events (harvest, packing, receiving, shipping, transforming) as specified in 21 CFR part 1, subpart S.
Large Estimated Compliance Burden Hours
FDA estimates the annual recordkeeping burden at 23,071,935 hours and total annual records at 2,981,605,187 across activities covered by 21 CFR part 1, subparts J and S; the agency reports no capital or operating and maintenance costs for this collection.
Public‑Health Benefit from Faster Tracebacks
These traceability record requirements help FDA more rapidly identify sources and recipients of contaminated foods, enabling faster removals from the market and reducing harm from foodborne illness or credible threats of serious adverse health consequences or death.
Record Retention Requirement: 2 Years
Records required under 21 CFR part 1, subpart S must be maintained for 2 years from the date they were created or obtained.
Small‑Business Relief, Exemptions, and Waivers
Although there is no statutory exception for small businesses, the regulations provide exemptions and partial exemptions (Secs. 1.327 and 1.1305), and businesses may request modified requirements or exemptions via citizen petition (Sec. 1.1370) or request waivers for economic hardship under Secs. 1.1415 and 1.1425; FDA also offers Regional Small Business Representatives and online assistance.
Existing Records May Satisfy Requirements
FDA states that existing records may be used to meet the requirements if they contain all required information and are retained for the required time period.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-15074, Medical Devices; Gastroenterology-Urology Devices; Classification of the Non-Medicated Topical Formulation for Treatment of Erectile Dysfunction
The Food and Drug Administration (FDA) is classifying the non- medicated topical formulation for treatment of erectile dysfunction into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the non-medicated topical formulation for treatment of erectile dysfunction. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-15075, Medical Devices; General Hospital and Personal Use Devices; Classification of the Active Noise Attenuation System for Infant Incubators
The Food and Drug Administration (FDA) is classifying the active noise attenuation system for infant incubators into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the active noise attenuation system for infant incubators. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-15070, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Radioactive Drug Research Committees
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
2026-14984, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Prognostic Test for Assessment of Chronic Kidney Disease Progression
The FDA is officially putting a special kidney disease test into Class II, meaning it’s safe and effective but with some extra rules to keep it that way. This change helps patients get access to this cool new test faster by cutting down red tape. The new classification is effective July 24, 2026, and could save companies time and money while making sure the test works well.
Previous / Next Documents
Previous: 2026-11759, Request for Comments on the Renewal of a Previously Approved Information Collection: Capital Construction Fund and Exhibits
The Maritime Administration wants to keep collecting info from U.S. ship owners who use the Capital Construction Fund, a special savings plan that helps them build or upgrade vessels by delaying some taxes. Fewer people are responding now, but the rules and forms won’t change. If you’re involved, you’ve got 30 days to share your thoughts—no extra costs or new paperwork coming your way!
Next: 2026-11762, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.